DPP-4 inhibitors, so-called incretin enhancers, are attracting attention among therapeutic agents for type 2 diabetes mellitus, since they improve glucose control with a low risk of hypoglycemia2, 3. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.